

## Supplementary Materials

### Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer


**Supplementary material S1.** Detailed information of neoadjuvant and adjuvant therapy.

<b>Neoadjuvant therapy (n=100)</b>	
CCRT with 5-FU	49 (49.0%)
CCRT with gemcitabine	13 (13.0%)
FOLFIRINOX	20 (20.0%)
Gemcitabine based CTx <sup>†</sup>	10 (10.0%)
Other CTx <sup>*</sup>	8 (8.0%)
<b>Adjuvant therapy (n=129)</b>	
Gemcitabine monotherapy	97 (75.2%)
Gemcitabine based combination CTx <sup>‡</sup>	4 (3.1%)
5-FU monotherapy	11 (8.5%)
5-FU based combination CTx <sup>‡‡</sup>	17 (13.2%)

Abbreviations: CCRT, concurrent chemoradiotherapy; 5-FU, 5-fluorouracil; CTx, chemotherapy. <sup>†</sup> Includes eight gemcitabine + erlotinib, one gemcitabine + nab-paclitaxel, and one gemcitabine therapy. <sup>\*</sup> Includes three capecitabine, three tegafur/uracil, and two 5-fluorouracil therapy. <sup>‡</sup> Includes three gemcitabine + erlotinib, and one gemcitabine + capecitabine therapy. <sup>‡‡</sup> Includes twelve 5-fluorouracil + etoposide + cisplatin, and five 5-fluorouracil + cisplatin therapy.


**Supplementary material S2.** Kaplan–Meier estimates of overall survival of stage groups according to the AJCC staging system, 8th edition in patient with confirmed adenocarcinoma **(A)** Comparison of stages (from I to IV), **(B)** Comparison of substages (from IA to IIB).

**(A)**



Stage group	Median OS, months (95% CI)		
I (n=234)	20.4 (17.3–23.5)		
II (n=59)	15.1 (11.0–19.2)		
III (n=163)	14.4 (12.5–16.3)		
IV (n=486)	6.1 (5.4–6.8)		
<i>P</i>	I	II	III
I			
II	0.225		
III	<b>&lt;0.001</b>	<b>0.026</b>	
IV	<b>&lt;0.001</b>	<b>&lt;0.001</b>	<b>&lt;0.001</b>


(B)



Stage group	Median OS, months (95% CI)		
IA (n=65)	35.8 (27.3–44.3)		
IB (n=169)	16.8 (14.3–19.3)		
IIA (n=33)	19.2 (4.7–33.7)		
IIB (n=26)	12.2 (5.0–19.4)		

P	IA	IB	IIA
IA			
IB	<0.001		
IIA	0.128	0.357	
IIB	<0.001	0.109	0.095

**Supplementary material S3.** Overall survival of non-metastatic pancreatic adenocarcinoma patients according to the AJCC staging system, 8th edition stratified by N staging.



N stage	Median OS, months (95% CI)
N0 (n=386)	17.9 (16.0–19.8)
N1 (n=58)	14.2 (10.8–17.6)
N2 (n=12)	7.2 (4.0–10.4)